Phase III
BeiGene is starting off the week with a bang. Late Sunday the company announced positive preliminary topline results from its Phase II trial of tislelizumab, the company’s investigational checkpoint inhibitor for relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).
Roche’s Tecentriq, in combination with chemotherapy, hit its co-primary endpoint of progression-free survival in a Phase III trial for non-small cell lung cancer patients. But, the Swiss pharma giant said the combination has so far failed to achieve statistical significance in overall survival, a co-primary trial endpoint.
Pfizer and Eli Lilly released results from its 16-week Phase III clinical trial in patients with osteoarthritis (OA) pain receiving a subcutaneous dose of tanezumab. The drug hit all three co-primary endpoints.
Fresh off its first Pipeline Day last week, Vivek Ramaswamy’s Roivant Sciences is taking aim at breaking into the Chinese market. Roivant has launched another company called Sinovant Sciences.
With flu season fast approaching, Genentech has some good news for people who are at high risk of complications from the illness.
The good news keeps coming for Janssen Pharmaceuticals’ SGLT2 diabetes drug Invokana. Late Monday the company said it was halting its Phase III chronic kidney disease trial early due to the fact that the drug had already achieved pre-specified efficacy data.
Four months after filing a supplemental New Drug Application with the U.S. Food and Drug Administration, Astellas and Pfizer snagged regulatory approval for Xtandi as a treatment for non-metastatic Castration-Resistant Prostate Cancer (CRPC).
One year after Vivek Ramaswamy launched Urovant Sciences to develop urological therapies, the company is now seeking $150 million from an initial public offering.
Amgen and UCB resubmitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Evenity (romosozumab).
Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.
PRESS RELEASES